Related references
Note: Only part of the references are listed.Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors
Jun Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases
Angela V. Toms et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition
Nadia J. Kershaw et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Apostolos Kontzias et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Janus Kinase Deregulation in Leukemia and Lymphoma
Edwin Chen et al.
IMMUNITY (2012)
Inborn Errors of Human JAKs and STATs
Jean-Laurent Casanova et al.
IMMUNITY (2012)
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
Rajintha M. Bandaranayake et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
The JAK2 exon 12 mutations: A comprehensive review
Linda M. Scott
AMERICAN JOURNAL OF HEMATOLOGY (2011)
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
Daniela Ungureanu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation
Arturo Sanz et al.
PLOS ONE (2011)
A new regulatory switch in a JAK protein kinase
Vickie Tsui et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2011)
Expression, purification, and characterization of TYK-2 kinase domain, a member of the Janus kinase family
Brian Korniski et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
Jill E. Chrencik et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors
Alexandra Dusa et al.
PLOS ONE (2010)
Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain
Troii Hall et al.
PROTEIN EXPRESSION AND PURIFICATION (2010)
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia
Lyndal Kearney et al.
BLOOD (2009)
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia
Amos Gaikwad et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation
Lequn Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Charles G. Mullighan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome
Tomohiko Sato et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2
Alexandra Dusa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Dani Bercovich et al.
LANCET (2008)
Jaks and cytokine receptors - An intimate relationship
Claude Haan et al.
BIOCHEMICAL PHARMACOLOGY (2006)
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
IS Lucet et al.
BLOOD (2006)
Emerging roles of pseudokinases
Jerome Boudeau et al.
TRENDS IN CELL BIOLOGY (2006)
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor
J Staerk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog
TJ Boggon et al.
BLOOD (2005)
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
P Saharinen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
P Saharinen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
